Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons

Vaccine

Volumn 29, Issue 47, 2011, Pages 8520-8529

  Wald, Anna ^a   Koelle, David M ^b   Fife, Kenneth ^c   Warren, Terri ^d   LeClair, Kenneth ^e,g   Chicz, Roman M ^e,g   Monks, Stephen ^e   Levey, Daniel L ^e   Musselli, Cristina ^e   Srivastava, Pramod K ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Westover Heights Clinic   (United States)

^e Antigenics Inc   (United States)

^f UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^g NONE

Author keywords

CD8 + T cell; Genital herpes; Heat shock protein; Therapeutic vaccine

Indexed keywords

AG 707; HEAT SHOCK COGNATE PROTEIN 70; HERPES SIMPLEX VACCINE; QS 21; RECOMBINANT HEAT SHOCK COGNATE PROTEIN 70; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; ALLERGY; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DIZZINESS; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLICULITIS; GENITAL HERPES; HEADACHE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HYPOKALEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INSOMNIA; LACERATION; MALE; MYALGIA; NAUSEA; NIGHT SWEAT; NOSE CONGESTION; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; RIGOR; SIDE EFFECT; SKIN CYST; SNEEZING; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA DISCHARGE; VIRUS REPLICATION; VIRUS SHEDDING;

ADJUVANTS, IMMUNOLOGIC; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HSC70 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 82455192355     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.046     Document Type: Article

References (51)

1. Straus S.E., Wald A., Kost R.G., McKenzie R., Langenberg A.G., Hohman P., et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997, 176(November (5)):1129-1134.
2. de Bruyn G., Vargas-Cortez M., Warren T., Tyring S.K., Fife K.H., Lalezari J., et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006, 24(February (7)):914-920.
3. Straus S.E., Corey L., Burke R.L., Savarese B., Barnum G., Krause P.R., et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994, 343(June (8911)):1460-1463.
4. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998, 101(April (7)):1500-1508.
5. Posavad C.M., Koelle D.M., Shaughnessy M.F., Corey L. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 1997, 94(September (19)):10289-10294.
6. Koelle D.M., Chen H.B., Gavin M.A., Wald A., Kwok W.W., Corey L. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol 2001, 166(March (6)):4049-4058.
7. Braun R.P., Payne L.G., Dong L. Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpes. Virol J 2006, 3:54.
8. Koelle D.M., Frank J.M., Johnson M.L., Kwok W.W. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol 1998, 72(September (9)):7476-7483.
9. Hosken N., McGowan P., Meier A., Koelle D.M., Sleath P., Wagener F., et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 2006, 80(June (11)):5509-5515.
10. Castelli C., Ciupitu A.M., Rini F., Rivoltini L., Mazzocchi A., Kiessling R., et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001, 61(January (1)):222-227.
11. Blachere N.E., Li Z., Chandawarkar R.Y., Suto R., Jaikaria N.S., Basu S., et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997, 186(October (8)):1315-1322.
12. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002, 2(March (3)):185-194.
13. Zugel U., Sponaas A.M., Neckermann J., Schoel B., Kaufmann S.H. gp96-peptide vaccination of mice against intracellular bacteria. Infect Immun 2001, 69(June (6)):4164-4167.
14. Sun H.X., Xie Y., Ye Y.P. Advances in saponin-based adjuvants. Vaccine 2009, 27(March (12)):1787-1796.
15. Garcon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10(April (4)):471-486.
16. Waite D.C., Jacobson E.W., Ennis F.A., Edelman R., White B., Kammer R., et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001, 19(July (28-29)):3957-3967.
17. Zhu J., Koelle D.M., Cao J., Vazquez J., Huang M.L., Hladik F., et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007, 204(March (3)):595-603.
18. Koelle D.M., Schomogyi M., Corey L., Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. J Infect Dis 2000, 182(September (3)):662-670.
19. Verjans G.M., Hintzen R.Q., van Dun J.M., Poot A., Milikan J.C., Laman J.D., et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A 2007, 104(February (9)):3496-3501.
20. Khanna K.M., Bonneau R.H., Kinchington P.R., Hendricks R.L. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003, 18(May (5)):593-603.
21. van Lint A.L., Kleinert L., Clarke S.R., Stock A., Heath W.R., Carbone F.R. Latent infection with herpes simplex virus is associated with ongoing CD8+ T-cell stimulation by parenchymal cells within sensory ganglia. J Virol 2005, 79(December (23)):14843-14851.
22. Liu T., Khanna K.M., Chen X., Fink D.J., Hendricks R.L. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000, 191(May (9)):1459-1466.
23. Schiffer J.T., Abu-Raddad L., Mark K.E., Zhu J., Selke S., Koelle D.M., et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A 2010, 107(November (44)):18973-18978.
24. Koelle D.M., Corey L., Burke R.L., Eisenberg R.J., Cohen G.H., Pichyangkura R., et al. Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 1994, 68(May (5)):2803-2810.
25. Kwok W.W., Liu A.W., Novak E.J., Gebe J.A., Ettinger R.A., Nepom G.T., et al. HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J Immunol 2000, 164(April (8)):4244-4249.
26. Chentoufi A.A., Zhang X., Lamberth K., Dasgupta G., Bettahi I., Nguyen A., et al. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol 2008, 180(January (1)):426-437.
27. Novak E.J., Liu A.W., Gebe J.A., Falk B.A., Nepom G.T., Koelle D.M., et al. Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens. J Immunol 2001, 166(June (11)):6665-6670.
28. Laing K.J., Magaret A.S., Mueller D.E., Zhao L., Johnston C., De Rosa S.C., et al. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol 2010, (July).
29. Posavad C.M., Remington M., Mueller D.E., Zhao L., Magaret A.S., Wald A., et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 2010, 184(March (6)):3250-3259.
30. Kim M., Taylor J., Sidney J., Mikloska Z., Bodsworth N., Lagios K., et al. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J Immunol 2008, 181(November (9)):6604-6615.
31. Posavad C.M., Wald A., Hosken N., Huang M.L., Koelle D.M., Ashley R.L., et al. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?. J Immunol 2003, 170(April (8)):4380-4388.
32. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361(November (19)):1838-1847.
33. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14(March (3)):303-313.
34. Delneste Y., Magistrelli G., Gauchat J., Haeuw J., Aubry J., Nakamura K., et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002, 17(September (3)):353-362.
35. Fischer N., Haug M., Kwok W.W., Kalbacher H., Wernet D., Dannecker G.E., et al. Involvement of CD91 and scavenger receptors in Hsp70-facilitated activation of human antigen-specific CD4+ memory T cells. Eur J Immunol 2010, 40(April (4)):986-997.
36. Evans T.G., McElrath M.J., Matthews T., Montefiori D., Weinhold K., Wolff M., et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 2001, 19(February (15-16)):2080-2091.
37. Pack C.D., Kumaraguru U., Suvas S., Rouse B.T. Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with Herpes Simplex Virus. Vaccine 2005, 23(May (27)):3526-3534.
38. Kumaraguru U., Suvas S., Biswas P.S., Azkur A.K., Rouse B.T. Concomitant helper response rescues otherwise low avidity CD8+ memory CTLs to become efficient effectors in vivo. J Immunol 2004, 172(March (6)):3719-3724.
39. Kumaraguru U., Gierynska M., Norman S., Bruce B.D., Rouse B.T. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J Virol 2002, 76(January (1)):136-141.
40. Pack C.D., Gierynska M., Rouse B.T. An intranasal heat shock protein based vaccination strategy confers protection against mucosal challenge with herpes simplex virus. Hum Vaccin 2008, 4(September-October (5)):360-364.
41. Navaratnam M., Deshpande M.S., Hariharan M.J., Zatechka D.S., Srikumaran S. Heat shock protein-peptide complexes elicit cytotoxic T-lymphocyte and antibody responses specific for bovine herpesvirus 1. Vaccine 2001, 19(January (11-12)):1425-1434.
42. Ciupitu A.M., Petersson M., O'Donnell C.L., Williams K., Jindal S., Kiessling R., et al. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med 1998, 187(March (5)):685-691.
43. Li H., Zhou M., Han J., Zhu X., Dong T., Gao G.F., et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 2005, 174(January (1)):195-204.
44. Koelle D.M., Magaret A., McClurkan C.L., Remington M.L., Warren T., Teofilovici F., et al. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive or HSV-2-infected subjects. Clin Vaccine Immunol 2008, 15(May (5)):773-782.
45. Castellino F., Boucher P.E., Eichelberg K., Mayhew M., Rothman J.E., Houghton A.N., et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000, 191(June (11)):1957-1964.
46. Bendz H., Ruhland S.C., Pandya M.J., Hainzl O., Riegelsberger S., Brauchle C., et al. Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J Biol Chem 2007, 282(October (43)):31688-31702.
47. Strbo N., Pahwa S., Kolber M.A., Gonzalez L., Fisher E., Podack E.R. Cell-secreted Gp96-Ig-peptide complexes induce lamina propria and intraepithelial CD8+ cytotoxic T lymphocytes in the intestinal mucosa. Mucosal Immunol 2010, 3(March (2)):182-192.
48. Obermaier B., Dauer M., Herten J., Schad K., Endres S., Eigler A. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol Proced Online 2003, 5:197-203.
49. Smith J.G., Joseph H.R., Green T., Field J.A., Wooters M., Kaufhold R.M., et al. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol 2007, 14(May (5)):527-537.
50. Janetzki S., Britten C.M., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J., et al. " MIATA" -minimal information about T cell assays. Immunity 2009, 31(October (4)):527-528.
51. Mo A, Musselli C, Chen H, Pappas J, Leclair K, Liu A, et al. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine 2011;(Jul 19), in press.